StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)

Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%

Castle Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Castle Biosciences's operating cash flow for the twelve months ending Sep 30, 2026 was $39.74M, down 35.7% year over year. For fiscal 2025 it was $64.35M, down 0.8% from the year before. The highest annual figure on record is $64.87M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$64.35M-0.8%
FY2024Dec 31, 2024$64.87M–
FY2023Dec 31, 2023-$5.63M–
FY2022Dec 31, 2022-$41.66M–
FY2021Dec 31, 2021-$18.98M-292.4%
FY2020Dec 31, 2020$9.87M+40.6%
FY2019Dec 31, 2019$7.02M–
FY2018Dec 31, 2018-$12.30M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$19.74M-12.8%
Q2 FY2026Jun 30, 2026$15.20M-27.0%
Q1 FY2026Mar 31, 2026-$22.13M–
Q4 FY2025Dec 31, 2025$26.93M+10.5%
Q3 FY2025Sep 30, 2025$22.63M-3.0%
Q2 FY2025Jun 30, 2025$20.82M-13.2%
Q1 FY2025Mar 31, 2025-$6.04M–
Q4 FY2024Dec 31, 2024$24.37M+31.1%
Q3 FY2024Sep 30, 2024$23.34M+365.6%
Q2 FY2024Jun 30, 2024$24.00M–
Q1 FY2024Mar 31, 2024-$6.84M–
Q4 FY2023Dec 31, 2023$18.59M–
Q3 FY2023Sep 30, 2023$5.01M–
Q2 FY2023Jun 30, 2023-$3.79M–
Q1 FY2023Mar 31, 2023-$25.44M–
Q4 FY2022Dec 31, 2022-$6.00M–
Q3 FY2022Sep 30, 2022-$5.22M–
Q2 FY2022Jun 30, 2022-$9.00M–
Q1 FY2022Mar 31, 2022-$21.43M–
Q4 FY2021Dec 31, 2021-$2.78M–
Q3 FY2021Sep 30, 2021-$6.13M–
Q2 FY2021Jun 30, 2021-$6.44M-147.7%
Q1 FY2021Mar 31, 2021-$3.63M–
Q4 FY2020Dec 31, 2020-$430.00K-109.6%
Q3 FY2020Sep 30, 2020-$2.96M-493.0%
Q2 FY2020Jun 30, 2020$13.50M+2701.0%
Q1 FY2020Mar 31, 2020-$251.00K-119.5%
Q4 FY2019Dec 31, 2019$4.49M–
Q3 FY2019Sep 30, 2019$752.00K–
Q2 FY2019Jun 30, 2019$482.00K–
Q1 FY2019Mar 31, 2019$1.29M–
Q4 FY2018Dec 31, 2018-$3.21M–
Q3 FY2018Sep 30, 2018-$1.88M–

More Castle Biosciences figures

See a number that looks wrong?